Abstract
Human parathyroid hormone 1–34 fragment (PTH1–34) has been used as a FDA-approved therapeutics to treat osteoporosis by daily subcutaneous injection. In this work, we successfully developed PTH1–34 conjugated hyaluronic acid (HA) for the transdermal treatment of osteoporosis with improved patient compliance. HA-PTH1–34 conjugate was synthesized by the coupling reaction between aldehyde group introduced to HA and amine group of PTH1–34. After characterization by gel permeation chromatography (GPC) and ELISA, the biological effect of HA-PTH1–34 conjugate on the proliferation of human osteoblast cells was confirmed by in vitro calcium colorimetric assay and cAMP assay. Two-photon microscopy clearly visualized the effective skin penetration of FITC modified HA-PTH1–34 conjugate. The transdermally delivered HA-PTH1–34 conjugates elevated the blood calcium concentration for more than 2 days, reflecting the feasibility for the treatment of osteoporosis.
Acknowledgements
We thank Gyu Seop Jo for the analysis with two-photon microscopy.